Delving into the Latest Updates on Botulinum toxin type A(HSM) with Synapse

Overview

Basic Info

Drug Type

Toxin

Synonyms

Botulinum Toxin Type A, 注射用重组A型肉毒毒素

+ [2]

Target

SNAP25

Action

inhibitors

Mechanism

SNAP25 inhibitors(Synaptosomal-associated protein 25 inhibitors)

Therapeutic Areas

Skin and Musculoskeletal DiseasesNervous System DiseasesOther Diseases

Active Indication

Glabellar frown linesUpper limb spasticity

Inactive Indication-

Originator Organization

JHM BioPharma (Tonghua) Co. , Ltd.

Active Organization

JHM BioPharma (Tonghua) Co. , Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of Eveotox in the treatment of moderate to severe glabellar lines. The study consists of Study Part 1 (randomized double-blind controlled study) and Part 2 (open-label study). Part I is a multicenter, randomized, double-blind, single-injection, active-controlled and placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of Eveotox in the treatment of moderate to severe glabellar lines; Part 2 is an open-label study to evaluate the efficacy, safety, and immunogenicity of repeated injections of Eveotox in the treatment of moderate to severe glabellar lines.

Start Date01 Apr 2025

Sponsor / Collaborator

JHM BioPharma (Tonghua) Co. , Ltd.

NCT06448676

/ Not yet recruitingPhase 4IIT

Head-to-Head Comparison of the Efficacy and Safety of All Five Commercially Available Botulinum Neurotoxin Type A Products for the Treatment of Glabellar Rhytides: A Multicenter, Triple-Blind, Randomized Controlled Trial

Study Type: This is a multicenter, triple-blind, randomized controlled trial.
Purpose: The goal of this clinical trial is to compare the effectiveness and safety of all five commercially available Botulinum Neurotoxin Type A (BoNT-A) products for treating glabellar rhytides, commonly known as frown lines. This study is designed to provide comprehensive data on how these treatments compare in terms of improving frown lines and the duration of their effects.
Main Questions the Study Aims to Answer:
Which BoNT-A product provides the longest lasting effect on reducing glabellar rhytides? How do these products compare in terms of safety and the occurrence of side effects?
Participant Tasks:
Women aged 18 years or older with moderate to severe glabellar lines will participate.
Participants will receive injections of a BoNT-A product into specific facial muscles.
They will need to take weekly photographs using their smartphones to document changes in their frown lines.
These photos will be securely sent to our research team for analysis. Participants will complete questionnaires at the start and end of the study to assess their satisfaction, quality of life, and any changes in their condition.
Comparison Group:
Researchers will compare participants receiving different types of BoNT-A products to see which one is more effective at reducing frown lines and maintaining these effects over time.
The safety profiles of these products will also be compared to determine which has the fewest and least severe side effects.
This study aims to fill important gaps in our understanding of Botulinum Neurotoxin Type A treatments, guiding more effective clinical decisions and improving patient outcomes.

Start Date01 Jan 2025

Sponsor / Collaborator-

IRCT20101012004920N10

/ SuspendedPhase 1IIT

Safety study on botulinum toxin type A of Plasma Darman Sarve Sepid Company

Start Date22 Sep 2024

Sponsor / Collaborator-

100 Clinical Results associated with Botulinum toxin type A(HSM)

Login to view more data

100 Translational Medicine associated with Botulinum toxin type A(HSM)

Login to view more data

100 Patents (Medical) associated with Botulinum toxin type A(HSM)

Login to view more data

2,483

Literatures (Medical) associated with Botulinum toxin type A(HSM)

01 Jul 2025·The Ocular Surface

Impact of botulinum toxin type A on ocular pain with neuropathic features

Article

Author: Lee, Wendy W ; Huang, Jaxon J ; Locatelli, Elyana V T ; Reyes, Nicholas ; Betz, Jason D ; Kantor, Nicole B ; Huang, Jordan J ; Galor, Anat ; Felix, Elizabeth R

PURPOSETo investigate the impact of botulinum toxin type A (BoNT-A) on neuropathic/nociplastic ocular pain (NOP) and identify predictors of patient outcomes.METHODSA retrospective study of individuals with NOP symptoms (light sensitivity, wind/air sensitivity, persistent pain despite dry eye treatment) who received ≥1 BoNT-A injection. Primary outcome measures included if (responders vs. non-responders) and to what degree (none vs. mild vs. moderate vs. marked) individuals experienced pain improvement 4-6 weeks post-injection. Demographics and clinical exam information was compared between the groups.RESULTS27 individuals received BoNT-A for NOP symptoms. 74 % (n = 20) reported an improvement in pain and were classified as responders. Among responders, the degree of benefit varied, with 25 % reporting mild, 45 % moderate, and 30 % marked pain improvement. Improvements in light sensitivity (37 %), wind/air sensitivity (33 %), and quality of life (QoL) (59 %) were reported by fewer individuals. 80 % of responders and 0 % of non-responders reported QoL improvements afer BoNT-A. In a multivariable model that examined predictors of response (none to marked, 0-3), the presence of fibromyalgia (FM) (β = 0.50; p = 0.004) portended a better response, while shooting pain (β = -0.47; p = 0.007) portended a worse response to BoNT-A, (full model r² = 0.53; p < 0.001). Degree of pain improvement significantly correlated with improvements in light sensitivity, wind/air sensitivity, and QoL (ρ range: 0.42-0.63; p < 0.05).CONCLUSIONAfter BoNT-A, most individuals reported improved ocular pain and QoL, while fewer noted improved light and wind/air sensitivity. Some systemic and ocular factors predicted treatment response and may thus guide treatment.

01 May 2025·Archives of Oral Biology

Botulinum toxin type A inhibits hyperalgesia in the rat masseter muscle in a carrageenan model of myofascial pain

Article

Author: Casais-E-Silva, Luciana Lyra ; Pinho, Pedro Paulo Pereira ; Aguiar, Marcio Cajazeira ; Neves, Ilana Dantas

OBJECTIVEPrevious studies have shown that botulinum toxin type A (BoNT-A) attenuates nociception, but the underlying mechanisms remain unclear. Studies of experimental pain in humans have also shown conflicting results. Carrageenan is commonly used to produce short-term acute inflammation and hyperalgesia in animal models, and the effect of BoNT-A on carrageenan-induced pain in the masseter muscle has not been studied. This study evaluated the antinociceptive and anti-inflammatory effects of intramuscular injection of BoNT-A in an experimental model of inflammatory pain in the masseter muscle of rats.DESIGNCarrageenan (2 %) was injected into the masseters of sixty rats pretreated with three sessions of BoNT-A (3.5 U/kg) or daily with ibuprofen (40 mg/kg) for seven days. Masseter injected with saline was used as a control. An electronic von Frey anesthesiometer determined the head withdrawal threshold before carrageenan and at 5 h, 1, 3, and 7 days following administration. The masseters were processed for paraffin embedding and H&E staining and subjected to histomorphometric analysis 1 and 8 days after carrageenan administration.RESULTSPretreatments with BoNT-A or ibuprofen significantly decreased carrageenan-induced hyperalgesia. BoNT-A did not inhibit inflammation and tissue damage induced by carrageenan.CONCLUSIONSThese findings reveal that BoNT-A promotes antinociceptive effects in the masseter muscle during painful conditions independently of anti-inflammatory mechanisms.

01 May 2025·Dermatologic Surgery

Effects of Botulinum Toxin Type A Treatment on Clinical and Biophysical Parameters in Patients With Erythematotelangiectatic Rosacea: A Prospective, Randomized, Controlled, Double-Blind Study

Article

Author: Avcı, Elif Bal ; Koku Aksu, Ayşe Esra ; Dağtaş, Buğra Burç ; Erdem, Ozan ; Güneç, Tuğba İlter ; Manav, Vildan

BACKGROUNDErythematotelangiectatic rosacea (ETR) lacks a gold-standard treatment. Recent studies show that intradermal Botulinum Toxin-A (BoNT-A) is effective for erythema, though objective data are limited.OBJECTIVEThis study aims to evaluate the efficacy and tolerability of intradermal BoNT-A in patients with ETR.METHODSIn this randomized, double-blind, split-face study, 30 patients were enrolled. One side of the face received 15 units of BoNT-A, reconstituted in 10 mL of saline, while the control side received saline injections. Assessments were made at baseline and 1-month posttreatment. Clinician's Erythema Assessment (CEA) scale and Patient Self-Assessment (PSA) scores were recorded. Erythema and Melanin Index measurements using a Mexameter. Background erythema was assessed through dermatoscopy, while vascular structure and density were evaluated using Investigative Global Assessment (IGA) scores through videocapillaroscopy.RESULTSThe BoNT-A-treated side demonstrated significant reductions in CEA scores, Erythema Index, and dermatoscopic background erythema, while no significant changes were observed on the saline control side. IGA scores indicated a significant response to treatment on the BoNT-A side. Patient Self-Assessment scores improved on both sides. No serious adverse events requiring hospitalization were reported.CONCLUSIONIntradermal BoNT-A effectively reduces erythema and vascular density in patients with ETR and is well-tolerated.

100 Deals associated with Botulinum toxin type A(HSM)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	M03AX01	-

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glabellar frown lines	Phase 3	China	JHM BioPharma (Tonghua) Co. , Ltd.	01 Apr 2025
Upper limb spasticity	Phase 2	China	JHM BioPharma (Tonghua) Co. , Ltd.	13 Sep 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


P11-12.007 (AAN2023)	Not Applicable	Trigeminal Neuralgia	5	Botulinum toxin type A	nmfghyctxz(hoxrigdhvc) = seen only in 1 patient after the first injection sgrxdinofy (geyxsfdfcw )	Positive	25 Apr 2023
MDS2022	Not Applicable	Neuralgia, Postherpetic \| Trigeminal Neuralgia	19	Botulinum Toxin Type A	ceoqkpjglu(xmmhdndvmh) = in 1 case eahaqaevkz (onxodlewcz )	-	15 Sep 2022
ARVO2017	Not Applicable	Blepharospasm	-	botulinum toxin type A (Normal volunteers)	(qbmmwwhfuv) = pexroiwfzb fxtrjojxdx (doncnbpyds )	Positive	07 May 2017
ARVO2017	Not Applicable	Blepharospasm	-	botulinum toxin type A (Patients with blepharospasm)	(qbmmwwhfuv) = pfepvxzisk fxtrjojxdx (doncnbpyds )	Positive	07 May 2017
MDS2016	Not Applicable	Blepharospasm	252	Botulinum toxin type A	dsavyoqrfb(mdyzffgvha): RR = 5.77 (95% CI, 1.82 - 18.34) View more	Positive	19 Jun 2016
MDS2016	Not Applicable	Blepharospasm	252	Placebo		Positive	19 Jun 2016
MDS2016	Not Applicable	Essential Tremor	21	Botulinum toxin type A	qjwfswdhfd(yxjlalxhxm) = bfxqjofygh vuoxkizqle (ngfdmtghuu ) View more	-	19 Jun 2016
P01.230 (AAN2012)	Not Applicable	Influenza-like symptoms	218	Botulinum Toxin Type A	sioydopcfx(fdkbukskcr) = FLS were reported by 20 (9.2%) patients zbwpiwdyur (dupgbaffjc ) View more	Positive	23 Apr 2012
ARVO2012	Not Applicable	Movement Disorders	334	Botulinum toxin type A	vvzecsiymm(syjczuelza) = oenveukobt xezatofbyf (wnvdalpdho ) View more	-	01 Mar 2012
ARVO2008	Not Applicable	Hemifacial Spasm	31	Botulinum toxin type A	(hjrsjaypkm) = xjvcwxjwcw wqnfjqhfzd (qdmatfjicm ) View more	-	01 May 2008
ARVO2006	Not Applicable	Migraine Disorders	17	Botulinum toxin type A	(xoxuyheqvh) = There were no reported adverse events fsrtcpgquc (ykbnglctyv ) View more	Positive	01 May 2006
ARVO2006	Not Applicable	Lateral Canthal Lines	13	Botulinum Toxin Type A	(fpkwbvrhif) = None of the patients developed dry eye symptoms 1 week and 1 month after botulinum toxin injection. Only one patient reported dry eye symptoms at 4 months follow-up. tlqwoqtfwc (wjsinggagm )	Positive	01 May 2006
ARVO2006	Not Applicable	Lateral Canthal Lines	13	Unpreserved Saline		Positive	01 May 2006

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data